dexchlorpheniramine (Rx)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

syrup

  • 2mg/5mL

Allergy Symptoms

2 mg PO q4-6hr

Dosage Forms & Strengths

syrup

  • 2mg/5mL

Allergy Symptoms

2-6 years: Syrup: 0.5 mg PO q4-6hr

6-11 years: (syrup) 1 mg PO q4-6hr

>12 years: As adults; (syrup) 2 mg PO q4-6hr

Dose at lower end of dosage range (2 mg PO q4-6hr) or administer less frequently

Nonanticholinergic antihistamines should be considered first when treating allergic reactions (Beers Criteria)

Avoid use in elderly because of high incidence of anticholinergic effects

Clearance reduced with advanced age, greater risk of confusion, dry mouth, constipation, and other anticholinergic effects and toxicity

May exacerbate existing lower urinary conditions or benign prostatic hyperplasia

Next:

Interactions

Interaction Checker

and dexchlorpheniramine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (6)

              • calcium/magnesium/potassium/sodium oxybates

                dexchlorpheniramine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • eluxadoline

                dexchlorpheniramine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.

              • metoclopramide intranasal

                dexchlorpheniramine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

              • pitolisant

                dexchlorpheniramine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.

              • sodium oxybate

                dexchlorpheniramine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • tranylcypromine

                tranylcypromine increases effects of dexchlorpheniramine by Other (see comment). Avoid or Use Alternate Drug. Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

              Monitor Closely (195)

              • albuterol

                dexchlorpheniramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • alfentanil

                dexchlorpheniramine and alfentanil both increase sedation. Use Caution/Monitor.

              • alprazolam

                dexchlorpheniramine and alprazolam both increase sedation. Use Caution/Monitor.

              • amifampridine

                dexchlorpheniramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.

              • amitriptyline

                dexchlorpheniramine and amitriptyline both increase sedation. Use Caution/Monitor.

              • amobarbital

                dexchlorpheniramine and amobarbital both increase sedation. Use Caution/Monitor.

              • amoxapine

                dexchlorpheniramine and amoxapine both increase sedation. Use Caution/Monitor.

              • apomorphine

                dexchlorpheniramine and apomorphine both increase sedation. Use Caution/Monitor.

              • arformoterol

                dexchlorpheniramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • aripiprazole

                dexchlorpheniramine and aripiprazole both increase sedation. Use Caution/Monitor.

              • armodafinil

                dexchlorpheniramine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • azelastine

                azelastine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • baclofen

                dexchlorpheniramine and baclofen both increase sedation. Use Caution/Monitor.

              • belladonna and opium

                dexchlorpheniramine and belladonna and opium both increase sedation. Use Caution/Monitor.

              • benperidol

                dexchlorpheniramine and benperidol both increase sedation. Use Caution/Monitor.

              • benzphetamine

                dexchlorpheniramine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • brexanolone

                brexanolone, dexchlorpheniramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.

              • brompheniramine

                brompheniramine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • buprenorphine

                dexchlorpheniramine and buprenorphine both increase sedation. Use Caution/Monitor.

              • buprenorphine buccal

                dexchlorpheniramine and buprenorphine buccal both increase sedation. Use Caution/Monitor.

              • butabarbital

                dexchlorpheniramine and butabarbital both increase sedation. Use Caution/Monitor.

              • butalbital

                dexchlorpheniramine and butalbital both increase sedation. Use Caution/Monitor.

              • butorphanol

                dexchlorpheniramine and butorphanol both increase sedation. Use Caution/Monitor.

              • caffeine

                dexchlorpheniramine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • carbinoxamine

                carbinoxamine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • carisoprodol

                dexchlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.

              • cenobamate

                cenobamate, dexchlorpheniramine. Either increases effects of the other by sedation. Use Caution/Monitor.

              • chloral hydrate

                dexchlorpheniramine and chloral hydrate both increase sedation. Use Caution/Monitor.

              • chlordiazepoxide

                dexchlorpheniramine and chlordiazepoxide both increase sedation. Use Caution/Monitor.

              • chlorpheniramine

                chlorpheniramine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • chlorpromazine

                dexchlorpheniramine and chlorpromazine both increase sedation. Use Caution/Monitor.

              • chlorzoxazone

                dexchlorpheniramine and chlorzoxazone both increase sedation. Use Caution/Monitor.

              • cinnarizine

                cinnarizine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • clemastine

                clemastine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • clobazam

                dexchlorpheniramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

              • clomipramine

                dexchlorpheniramine and clomipramine both increase sedation. Use Caution/Monitor.

              • clonazepam

                dexchlorpheniramine and clonazepam both increase sedation. Use Caution/Monitor.

              • clorazepate

                dexchlorpheniramine and clorazepate both increase sedation. Use Caution/Monitor.

              • clozapine

                dexchlorpheniramine and clozapine both increase sedation. Use Caution/Monitor.

              • codeine

                dexchlorpheniramine and codeine both increase sedation. Use Caution/Monitor.

              • cyclizine

                cyclizine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • cyclobenzaprine

                dexchlorpheniramine and cyclobenzaprine both increase sedation. Use Caution/Monitor.

              • cyproheptadine

                cyproheptadine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • dantrolene

                dexchlorpheniramine and dantrolene both increase sedation. Use Caution/Monitor.

              • desflurane

                desflurane and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • desipramine

                dexchlorpheniramine and desipramine both increase sedation. Use Caution/Monitor.

              • deutetrabenazine

                dexchlorpheniramine and deutetrabenazine both increase sedation. Use Caution/Monitor.

              • dexfenfluramine

                dexchlorpheniramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexmedetomidine

                dexchlorpheniramine and dexmedetomidine both increase sedation. Use Caution/Monitor.

              • dexmethylphenidate

                dexchlorpheniramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dextroamphetamine

                dexchlorpheniramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dextromoramide

                dexchlorpheniramine and dextromoramide both increase sedation. Use Caution/Monitor.

              • diamorphine

                dexchlorpheniramine and diamorphine both increase sedation. Use Caution/Monitor.

              • diazepam

                dexchlorpheniramine and diazepam both increase sedation. Use Caution/Monitor.

              • diazepam intranasal

                diazepam intranasal, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.

              • diethylpropion

                dexchlorpheniramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • difenoxin hcl

                dexchlorpheniramine and difenoxin hcl both increase sedation. Use Caution/Monitor.

              • dimenhydrinate

                dexchlorpheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • diphenhydramine

                dexchlorpheniramine and diphenhydramine both increase sedation. Use Caution/Monitor.

              • diphenoxylate hcl

                dexchlorpheniramine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.

              • dipipanone

                dexchlorpheniramine and dipipanone both increase sedation. Use Caution/Monitor.

              • dobutamine

                dexchlorpheniramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dopamine

                dexchlorpheniramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dopexamine

                dexchlorpheniramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dosulepin

                dexchlorpheniramine and dosulepin both increase sedation. Use Caution/Monitor.

              • doxepin

                dexchlorpheniramine and doxepin both increase sedation. Use Caution/Monitor.

              • doxylamine

                dexchlorpheniramine and doxylamine both increase sedation. Use Caution/Monitor.

              • droperidol

                dexchlorpheniramine and droperidol both increase sedation. Use Caution/Monitor.

              • ephedrine

                dexchlorpheniramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • epinephrine

                dexchlorpheniramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • epinephrine racemic

                dexchlorpheniramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • esketamine intranasal

                esketamine intranasal, dexchlorpheniramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

              • estazolam

                dexchlorpheniramine and estazolam both increase sedation. Use Caution/Monitor.

              • ethanol

                dexchlorpheniramine and ethanol both increase sedation. Use Caution/Monitor.

              • etomidate

                etomidate and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • fenfluramine

                dexchlorpheniramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fentanyl

                fentanyl, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl intranasal

                fentanyl intranasal, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transdermal

                fentanyl transdermal, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transmucosal

                fentanyl transmucosal, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • flibanserin

                dexchlorpheniramine and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.

              • fluphenazine

                dexchlorpheniramine and fluphenazine both increase sedation. Use Caution/Monitor.

              • flurazepam

                dexchlorpheniramine and flurazepam both increase sedation. Use Caution/Monitor.

              • formoterol

                dexchlorpheniramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • gabapentin

                gabapentin, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • gabapentin enacarbil

                gabapentin enacarbil, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • glycopyrronium tosylate topical

                glycopyrronium tosylate topical, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

              • gotu kola

                gotu kola increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • haloperidol

                dexchlorpheniramine and haloperidol both increase sedation. Use Caution/Monitor.

              • hawthorn

                hawthorn increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • hops

                hops increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • hyaluronidase

                dexchlorpheniramine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.

              • hydromorphone

                dexchlorpheniramine and hydromorphone both increase sedation. Use Caution/Monitor.

              • hydroxyzine

                dexchlorpheniramine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • iloperidone

                dexchlorpheniramine and iloperidone both increase sedation. Use Caution/Monitor.

              • imipramine

                dexchlorpheniramine and imipramine both increase sedation. Use Caution/Monitor.

              • isoproterenol

                dexchlorpheniramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • kava

                kava increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • ketamine

                ketamine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • ketotifen, ophthalmic

                dexchlorpheniramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

              • lasmiditan

                lasmiditan, dexchlorpheniramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

              • lemborexant

                lemborexant, dexchlorpheniramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

              • levalbuterol

                dexchlorpheniramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • levorphanol

                dexchlorpheniramine and levorphanol both increase sedation. Use Caution/Monitor.

              • lisdexamfetamine

                dexchlorpheniramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lofepramine

                dexchlorpheniramine and lofepramine both increase sedation. Use Caution/Monitor.

              • lofexidine

                dexchlorpheniramine and lofexidine both increase sedation. Use Caution/Monitor.

              • loprazolam

                dexchlorpheniramine and loprazolam both increase sedation. Use Caution/Monitor.

              • lorazepam

                dexchlorpheniramine and lorazepam both increase sedation. Use Caution/Monitor.

              • lormetazepam

                dexchlorpheniramine and lormetazepam both increase sedation. Use Caution/Monitor.

              • loxapine

                dexchlorpheniramine and loxapine both increase sedation. Use Caution/Monitor.

              • loxapine inhaled

                dexchlorpheniramine and loxapine inhaled both increase sedation. Use Caution/Monitor.

              • lurasidone

                lurasidone, dexchlorpheniramine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

              • maprotiline

                dexchlorpheniramine and maprotiline both increase sedation. Use Caution/Monitor.

              • marijuana

                dexchlorpheniramine and marijuana both increase sedation. Use Caution/Monitor.

              • melatonin

                dexchlorpheniramine and melatonin both increase sedation. Use Caution/Monitor.

              • meperidine

                dexchlorpheniramine and meperidine both increase sedation. Use Caution/Monitor.

              • meprobamate

                dexchlorpheniramine and meprobamate both increase sedation. Use Caution/Monitor.

              • metaproterenol

                dexchlorpheniramine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • metaxalone

                dexchlorpheniramine and metaxalone both increase sedation. Use Caution/Monitor.

              • methadone

                dexchlorpheniramine and methadone both increase sedation. Use Caution/Monitor.

              • methamphetamine

                dexchlorpheniramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • methocarbamol

                dexchlorpheniramine and methocarbamol both increase sedation. Use Caution/Monitor.

              • methylenedioxymethamphetamine

                dexchlorpheniramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • midazolam

                dexchlorpheniramine and midazolam both increase sedation. Use Caution/Monitor.

              • midazolam intranasal

                midazolam intranasal, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

              • midodrine

                dexchlorpheniramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • mirtazapine

                dexchlorpheniramine and mirtazapine both increase sedation. Use Caution/Monitor.

              • modafinil

                dexchlorpheniramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • morphine

                dexchlorpheniramine and morphine both increase sedation. Use Caution/Monitor.

              • motherwort

                dexchlorpheniramine and motherwort both increase sedation. Use Caution/Monitor.

              • moxonidine

                dexchlorpheniramine and moxonidine both increase sedation. Use Caution/Monitor.

              • nabilone

                dexchlorpheniramine and nabilone both increase sedation. Use Caution/Monitor.

              • nalbuphine

                dexchlorpheniramine and nalbuphine both increase sedation. Use Caution/Monitor.

              • norepinephrine

                dexchlorpheniramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nortriptyline

                dexchlorpheniramine and nortriptyline both increase sedation. Use Caution/Monitor.

              • olanzapine

                dexchlorpheniramine and olanzapine both increase sedation. Use Caution/Monitor.

              • opium tincture

                dexchlorpheniramine and opium tincture both increase sedation. Use Caution/Monitor.

              • orphenadrine

                dexchlorpheniramine and orphenadrine both increase sedation. Use Caution/Monitor.

              • oxazepam

                dexchlorpheniramine and oxazepam both increase sedation. Use Caution/Monitor.

              • oxycodone

                dexchlorpheniramine and oxycodone both increase sedation. Use Caution/Monitor.

              • oxymorphone

                dexchlorpheniramine and oxymorphone both increase sedation. Use Caution/Monitor.

              • paliperidone

                dexchlorpheniramine and paliperidone both increase sedation. Use Caution/Monitor.

              • papaveretum

                dexchlorpheniramine and papaveretum both increase sedation. Use Caution/Monitor.

              • papaverine

                dexchlorpheniramine and papaverine both increase sedation. Use Caution/Monitor.

              • passion flower

                passion flower increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • pentazocine

                dexchlorpheniramine and pentazocine both increase sedation. Use Caution/Monitor.

              • pentobarbital

                dexchlorpheniramine and pentobarbital both increase sedation. Use Caution/Monitor.

              • perphenazine

                dexchlorpheniramine and perphenazine both increase sedation. Use Caution/Monitor.

              • phendimetrazine

                dexchlorpheniramine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenelzine

                phenelzine increases effects of dexchlorpheniramine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

              • phenobarbital

                dexchlorpheniramine and phenobarbital both increase sedation. Use Caution/Monitor.

              • phentermine

                dexchlorpheniramine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenylephrine

                dexchlorpheniramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenylephrine PO

                dexchlorpheniramine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • pholcodine

                dexchlorpheniramine and pholcodine both increase sedation. Use Caution/Monitor.

              • pimozide

                dexchlorpheniramine and pimozide both increase sedation. Use Caution/Monitor.

              • pirbuterol

                dexchlorpheniramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pregabalin

                pregabalin, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • primidone

                dexchlorpheniramine and primidone both increase sedation. Use Caution/Monitor.

              • prochlorperazine

                dexchlorpheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.

              • promethazine

                dexchlorpheniramine and promethazine both increase sedation. Use Caution/Monitor.

              • propofol

                propofol and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • propylhexedrine

                dexchlorpheniramine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • protriptyline

                dexchlorpheniramine and protriptyline both increase sedation. Use Caution/Monitor.

              • quazepam

                dexchlorpheniramine and quazepam both increase sedation. Use Caution/Monitor.

              • quetiapine

                dexchlorpheniramine and quetiapine both increase sedation. Use Caution/Monitor.

              • ramelteon

                dexchlorpheniramine and ramelteon both increase sedation. Use Caution/Monitor.

              • risperidone

                dexchlorpheniramine and risperidone both increase sedation. Use Caution/Monitor.

              • salmeterol

                dexchlorpheniramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • scullcap

                dexchlorpheniramine and scullcap both increase sedation. Use Caution/Monitor.

              • secobarbital

                dexchlorpheniramine and secobarbital both increase sedation. Use Caution/Monitor.

              • sevoflurane

                sevoflurane and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • shepherd's purse

                dexchlorpheniramine and shepherd's purse both increase sedation. Use Caution/Monitor.

              • stiripentol

                stiripentol, dexchlorpheniramine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

              • sufentanil

                dexchlorpheniramine and sufentanil both increase sedation. Use Caution/Monitor.

              • tapentadol

                dexchlorpheniramine and tapentadol both increase sedation. Use Caution/Monitor.

              • temazepam

                dexchlorpheniramine and temazepam both increase sedation. Use Caution/Monitor.

              • terbutaline

                dexchlorpheniramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • thioridazine

                dexchlorpheniramine and thioridazine both increase sedation. Use Caution/Monitor.

              • thiothixene

                dexchlorpheniramine and thiothixene both increase sedation. Use Caution/Monitor.

              • topiramate

                dexchlorpheniramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.

              • tramadol

                dexchlorpheniramine and tramadol both increase sedation. Use Caution/Monitor.

              • trazodone

                dexchlorpheniramine and trazodone both increase sedation. Use Caution/Monitor.

              • triazolam

                dexchlorpheniramine and triazolam both increase sedation. Use Caution/Monitor.

              • triclofos

                dexchlorpheniramine and triclofos both increase sedation. Use Caution/Monitor.

              • trifluoperazine

                dexchlorpheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.

              • trimipramine

                dexchlorpheniramine and trimipramine both increase sedation. Use Caution/Monitor.

              • triprolidine

                dexchlorpheniramine and triprolidine both increase sedation. Use Caution/Monitor.

              • valerian

                valerian increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • xylometazoline

                dexchlorpheniramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • yohimbine

                dexchlorpheniramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ziconotide

                dexchlorpheniramine and ziconotide both increase sedation. Use Caution/Monitor.

              • ziprasidone

                dexchlorpheniramine and ziprasidone both increase sedation. Use Caution/Monitor.

              • zotepine

                dexchlorpheniramine and zotepine both increase sedation. Use Caution/Monitor.

              Minor (6)

              • ashwagandha

                ashwagandha increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

              • brimonidine

                brimonidine increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • eucalyptus

                dexchlorpheniramine and eucalyptus both increase sedation. Minor/Significance Unknown.

              • nettle

                nettle increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.

              • sage

                dexchlorpheniramine and sage both increase sedation. Minor/Significance Unknown.

              • Siberian ginseng

                Siberian ginseng increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: B

              Lactation: excretion in milk unknown/not recommended

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Histamine H1-receptor antagonist in blood vessels, respiratory tract, and gastrointestinal tract

              Pharmacokinetics

              Half-Life: 20-30 hr

              Onset: 6 hr

              Duration: 24 hr

              Peak Plasma Time: 3 hr

              Protein Bound: 69-72%

              Excretion: Urine

              Vd: 2.5-3.2 L/kg (adults); 3.8 L/kg (Children)

              Metabolism: Hepatic

              Metabolites: Unidentified, at least 2

              Sedative effects: Low

              Antihistamine activity: High

              Anticholinergic activity: Moderate

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.